Abstract
In metastatic colorectal cancer, a combination of Leucovorin (LV) and fluorouraci (l FU) with oxaliplatin (FOLFOX) is a standard first-line regimen. The two limiting toxicities of FOLFOX are neutropenia and the specific reversible sensory neuropathy of oxaliplatin. The cumulative neurotoxicity often requires therapy to be stopped. Immediate hypersensitive reactions (anaphylaxis) have been noted as often as to 0.6 percent. We should pay sufficient attention to side effects of FOLFOX.
MeSH terms
-
Anaphylaxis / chemically induced
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Drug Administration Schedule
-
Fluorouracil / administration & dosage
-
Fluorouracil / adverse effects
-
Guideline Adherence*
-
Humans
-
Leucovorin / administration & dosage
-
Leucovorin / adverse effects
-
Neoplasms / drug therapy*
-
Neutropenia / chemically induced
-
Organoplatinum Compounds / administration & dosage
-
Organoplatinum Compounds / adverse effects
-
Practice Guidelines as Topic
Substances
-
Organoplatinum Compounds
-
Leucovorin
-
Fluorouracil